전체보기 학술정보센터 (2)건 |
KMCRIC TV |
전체보기 한의약융합데이터센터 (146)건 | ||||
근거중심한의약 DB | ||||
[체계적 문헌고찰] Phytother Res. 2020 Herbal medicines and phytochemicals for obsessive-compulsive disorder. | ||||
[체계적 문헌고찰] Planta Med. 2019 The Efficacy of Saffron in the Treatment of Mild to Moderate Depression: A Meta-analysis. | ||||
약물상호작용 DB | ||||
[한약-양약 상호작용]
St. John's wort is an inducer of cytochrome P450 enzymes, particularly the CYP3A4 and CYP1A2 family [40;160;208;209;210;211]. Moore et al. demonstrated that St. John's wort (hyperforin) acti
...
... 보고되었다 [215;216]. 가용 혈장 자료에 대한 19개 실험의 한 체계적 문헌 고찰에서, 3개의 실험은 세인트존스워트와 의약품 사이의 주요한 상호 작용의 부재에 대하여 보고하였고, 17개의 실험은 기존 약물의 전신...
|
||||
[한약-식이보충제 상호작용]
St. John's wort is an inducer of cytochrome P450 enzymes, particularly the CYP3A4 and CYP1A2 family [40;160;208;209;210;211]. Moore et al. demonstrated that St. John's wort (hyperforin) acti
...
... 보고되었다 [215;216]. 가용 혈장 자료에 대한 19개 실험의 한 체계적 문헌 고찰에서, 3개의 실험은 세인트존스워트와 의약품 사이의 주요한 상호 작용의 부재에 대하여 보고하였고, 17개의 실험은 기존 약물의 전신...
|
전체보기 지식솔루션센터 (1)건 |
생활 속 한의 |
KMCRIC TV |
근거중심한의약 DB |
[체계적 문헌고찰] Phytother Res. 2020 Herbal medicines and phytochemicals for obsessive-compulsive disorder. |
[체계적 문헌고찰] Planta Med. 2019 The Efficacy of Saffron in the Treatment of Mild to Moderate Depression: A Meta-analysis. |
약물상호작용 DB | ||||
[한약-양약 상호작용]
St. John's wort is an inducer of cytochrome P450 enzymes, particularly the CYP3A4 and CYP1A2 family [40;160;208;209;210;211]. Moore et al. demonstrated that St. John's wort (hyperforin) activates a regulator [pregnane X receptor] of CYP3A4 transcription and thereby induces expression of 3A4 in human liver cells [212]. Bray et al. demonstrated induction of 3A and 2E1 in mice [213]. Upon review, it was noted that St. John's wort may inhibit CYP3A4 acutely and then induce this enzyme with repeated administration [45;214]. CYP2C9, 2D6, and 3A4 inhibition has also been reported in in vivo and in vitro research [215;216]. In a systematic review of 19 trials with available plasma data, three reported a lack of important interaction between St. John's wort and pharmaceutical drugs, and 17 described a decrease in systemic bioavailability of a conventional drug [4]. According to in vitro, animal, and human studies, concurrent use of drugs metabolized via the CYP450 liver enzyme system may result in altered therapeutic levels of pharmacologic agents, due to induction or inhibition of enzymes by St. John's wort [217;215;216;213;45;18;19;40;20;218;219;125;220;221;222]. However, other studies failed to show such induction or inhibition of enzymes [19;219;125;171;223]. In a human case study, a psychiatric patient had symptoms due to decreased levels of clozapine, brought on by taking St. John's wort [160]. In human research, cyclosporine was at subtherapeutic levels due to St. John's wort coadministration, which resulted in organ rejection in a case study [203;204]. In in vitro research, St. John's wort induced CYP450 2C9 [125]. According to case reports and clinical research, St. John's wort has a cytochrome P450- or p-glycoprotein-mediated interaction with anesthetics, vasopressors, buspirone, bupropion, eletriptan, nefazodone, loperamide, nevirapine, paroxetine, phenprocoumon, sertraline, prednisone, theophylline, tacrolimus, tryptophan, tibolone, and venlafaxine, and an interaction that causes a decrease in the levels of alprazolam, amitriptyline, cyclosporine, debrisoquine, atorvastatin, chlorzoxazone, digoxin, erythromycin, imatinib, indinavir, fexofenadine, gliclazide, irinotecan, ivabradine, midazolam, nifedipine, mephenytoin, methadone, omeprazole, oral contraceptives, tacrolimus, talinolol, verapamil, quazepam, simvastatin, voriconazole, and warfarin [211]. Treatment with high-dose hyperforin extracts (>10mg daily) has been associated with CYP3A induction. However, low-dose treatments (<4mg daily) lacked this interaction [97;30].
... 보고되었다 [215;216]. 가용 혈장 자료에 대한 19개 실험의 한 체계적 문헌 고찰에서, 3개의 실험은 세인트존스워트와 의약품 사이의 주요한 상호 작용의 부재에 대하여 보고하였고, 17개의 실험은 기존 약물의 전신...
|
||||
[한약-식이보충제 상호작용]
St. John's wort is an inducer of cytochrome P450 enzymes, particularly the CYP3A4 and CYP1A2 family [40;160;208;209;210;211]. Moore et al. demonstrated that St. John's wort (hyperforin) activates a regulator (pregnane X receptor) of CYP3A4 transcription and thereby induces expression of 3A4 in human liver cells [212]. Bray et al. demonstrated induction of 3A and 2E1 in mice [213]. Upon review, it was noted that St. John's wort may inhibit CYP3A4 acutely and then induce this enzyme with repeated administration [45;214]. CYP2C9, 2D6, and 3A4 inhibition has also been reported in in vivo and in vitro research [215;216]. In a systematic review of 19 trials with available plasma data, three reported a lack of important interaction between St. John's wort and pharmaceutical drugs, and 17 described a decrease in systemic bioavailability of a conventional drug [4]. According to in vitro, animal, and human studies, concurrent use of drugs metabolized via the CYP450 liver enzyme system may result in altered therapeutic levels of pharmacologic agents, due to induction or inhibition of enzymes by St. John's wort [217;215;216;213;45;18;19;40;20;218;219;125;220;221;222]. However, other studies have failed to show such induction or inhibition of enzymes [19;219;125;171;223]. In a human case study, a psychiatric patient had symptoms due to decreased levels of clozapine, brought on by taking St. John's wort [160]. In human research, cyclosporine was at subtherapeutic levels due to St. John's wort coadministration, which resulted in organ rejection in a case study [203;204]. Treatment with high-dose hyperforin extracts (>10mg daily) has been associated with CYP3A induction. However, low dose treatments (<4mg daily) lacked this interaction [97;30].
... 보고되었다 [215;216]. 가용 혈장 자료에 대한 19개 실험의 한 체계적 문헌 고찰에서, 3개의 실험은 세인트존스워트와 의약품 사이의 주요한 상호 작용의 부재에 대하여 보고하였고, 17개의 실험은 기존 약물의 전신...
|
의료인의 서재 |